Busulfan 12 mg/kg plus melphalan 140 mg/m(2) versus melphalan 200 mg/m(2) as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

BACKGROUND: The aim of this study was to compare the long-term safety and efficacy of oral busulfan 12 mg/kg plus melphalan 140 mg/m(2) and melphalan 200 mg/m(2) as conditioning regimens for autologous stem cell transplantation in newly diagnosed patients with multiple myeloma in the GEM2000 study....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lahuerta, Juan José, Mateos, Maria Victoria, Martínez-López, Joaquin, Grande, Carlos, de la Rubia, Javier, Rosiñol, Laura, Sureda, Anna, García-Laraña, José, Díaz-Mediavilla, Joaquín, Hernández-García, Miguel T., Carrera, Dolores, Besalduch, Joan, de Arriba, Felipe, Oriol, Albert, Escoda, Lourdes, García-Frade, Javier, Rivas-González, Concepción, Alegre, Adrían, Bladé, Joan, San Miguel, Jesús F.
Formato: Artigo
Lenguaje:Inglês
Publicado: Ferrata Storti Foundation 2010
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2966914/
https://ncbi.nlm.nih.gov/pubmed/20663944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.028027
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares